Diligent Launches AI Act Toolkits to Support Organizations in Complying with New EU AI Regulation
18.9.2024 10:00:00 CEST | Business Wire | Press release
Toolkits enable customers to identify AI systems, classify associated risk, ensure compliance with the EU's AI Act obligations and uphold global ethical best practices.
Diligent, a leading GRC SaaS company, today announced the launch of its new Artificial Intelligence (AI) Act Toolkits, designed to help corporate secretaries, legal and compliance teams, chief technology officers, chief information security officers and audit teams navigate the increasing complexity of AI governance and AI regulatory compliance. The Toolkits empower businesses operating inside and outside the European Union (EU) to understand and comply with the requirements of the EU's AI Act, and to integrate a responsible and ethical approach to AI adoption that builds trust in new technologies and adheres to global standards for AI governance.
“As the AI landscape evolves, organizations are challenged to balance innovation with regulatory compliance and ethical considerations,” said Keith Fenner, Senior Vice President & General Manager, International at Diligent. “The EU's AI Act represents a significant regulatory milestone to ensure AI systems are safe, transparent, and respect fundamental rights. We’re thrilled to offer a solution that helps customers identify and map regulatory obligations, implement best practice controls, and govern AI responsibly. This ensures compliance with evolving global regulations while accelerating the adoption of AI technology and delivering value.”
There are three toolkits available within the Diligent One Platform:
- AI Discovery and Risk Classification Toolkit – This toolkit helps customers identify their AI systems and perform the required risk classification exercise. It also provides access to an extensive library of AI literacy and best practice governance resources for the board, senior management and employees to accelerate organizational readiness and elevate AI governance. The toolkit is available to all Diligent One Platform customers.
- AI Act IT Compliance Toolkit – This toolkit helps organizations understand regulatory requirements, map them against suggested controls, and document compliance. It offers suggested control mapping to the AI Act’s regulatory requirements, gap identification, a dashboard summary for control assessment, a remediation summary and notifications to key stakeholders.
- AI Act Risk Management Toolkit – This comprehensive risk management toolkit supports a complete AI governance program. It features a risk heatmap for reviewing and prioritizing risks, a dashboard summarizing AI systems by risk level, a pre-configured AI threat library, and tools for continuous monitoring to ensure policy adherence and compliance.
In a world where, according to surveys, 78% of employees bring their own AI tools to work and 86% of businesses use some form of AI without the board’s awareness, Diligent's AI Act Toolkits are designed to support compliance, governance and risk management efforts. The Toolkits help customers to identify their AI systems and models, apply a risk-based classification, understand their obligations as providers and deployers under the AI Act, build an AI governance framework and monitor ongoing compliance. This helps to ensure that AI systems are implemented responsibly and ethically, and in a manner that documents compliance efforts in accordance with customer, partner, employee and regulator expectations.
Diligent’s Toolkits provide a robust framework for assessing and managing the risks associated with AI systems, helping organizations incorporate ethical considerations into their AI development, and supporting ongoing compliance with the EU’s AI Act. As AI becomes increasingly integral to business strategy, the Toolkits reflect Diligent's dedication to supporting ethical AI practices and helping its customers stay ahead of regulatory changes.
To learn more about the AI Act Toolkits from Diligent, visit: https://www.diligent.com/lp/eu-ai-act-compliance
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918400561/en/
Contacts
Media
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom